NASDAQ · MYMD
Healthcare · Biotechnology
$1.81
Down-$0.01 (-0.55%)
Updated Sep 18, 2026, 6:07 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MYMD does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MYMD.
MYMD research
Company profile and research snapshot.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
PennyStocks · Jul 11, 2022
Here's what you need to know about trading penny stocks on July 11th The post What to Know About Buying Penny Stocks on July 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Benzinga · Jul 8, 2022
U.S. stocks turned higher midway through trading as investors digested the recent jobs report for the month of June. The Dow traded up 0.21% to 31,450.12 while the NASDAQ rose 0.21% to 11,646.33. The S&P also rose, gaining, 0.10% to 3,906.65. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Health care shares rose by 0.9% on Friday. Meanwhile, top gainers in the sector included MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD), up 30% and Clovis Oncology, Inc. (NASDAQ: CLVS) up 42%. In trading on Friday, utilities shares dipped by 0.5%. Top Headline The US economy added 372,000 payrolls in June, following a revised 384,000 growth in May. Analysts, however, were expecting for a 268,000 gain in jobs. Average hourly earnings for all employees on private nonfarm payrolls increased 0.3% to $32.08 in June. The US unemployment rate came in unchanged at 3.6% in June. Equities Trading UP Seritage Growth Properties (NYSE: SRG) shares shot up 68% to $10.23 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale. Shares of Aditxt, Inc. (NASDAQ: ADTX) got a boost, shooting ...
Benzinga · Jul 8, 2022
U.S. stocks traded lower this morning following the release of jobs report for the month of June. Following the market opening Friday, the Dow traded down 0.40% to 31,259.22 while the NASDAQ fell 0.92% to 11,514.48. The S&P also fell, dropping, 0.65% to 3,877.42. Also check this: GameStop, Levi Strauss And 3 Stocks To Watch Heading Into Friday Leading and Lagging Sectors Health care shares rose by 0.4% on Friday. Meanwhile, top gainers in the sector included MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD), up 20% and iRhythm Technologies, Inc. (NASDAQ: IRTC) up 22%. In trading on Friday, materials shares dipped by 1.2%. Top Headline The US economy added 372,000 payrolls in June, following a revised 384,000 growth in May. Analysts, however, were expecting for a 268,000 gain in jobs. Average hourly earnings for all employees on private nonfarm payrolls increased 0.3% to $32.08 in June. The US unemployment rate came in unchanged at 3.6% in June. Equities Trading UP Seritage Growth Properties (NYSE: SRG) shares shot up 52% to $9.24 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recommended shareholders to approve a proposed plan sale. Shares of Clovis Oncology, Inc. (NASDAQ: CLVS) got a boost, shooting 36% to ...
Benzinga · Oct 6, 2021
Benzinga is thrilled to announce the guest lineup for our next All Access show, set to air Thursday, October 7 at 9:00 am ET. Thursday's Guest Lineup The theme of Thursday's All Access is Rising Stars. We're focusing on small-cap growth stocks that are rising stars in their industries and have clear upcoming catalysts. Here's the guest lineup: Leonard Mazur, Chairman of the Board - Citius Pharmaceuticals (NASDAQ: CTXR) Website Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in adjunct cancer care, oncology, stem cell therapy and unique prescription products. Mark Frohnmayer, Founder & President - Arcimoto (NASDAQ: FUV) Website Arcimoto is an electric vehicle company headquartered in Eugene, Oregon that manufactures and sells the Fun Utility Vehicle, or FUV, a tandem two-seat, three-wheeled electric vehicle. They also sell van-variations on the design "Rapid Responder" for emergency services, and "Deliverator" for last-mile deliveries. Dr. Adam Kaplin, M.D., Ph.D., CSO - MyMD (NASDAQ: MYMD) Website MyMD Pharmaceuticals is a clinical stage pharmaceutical company committed to extending healthy lifespan. Currently, we are developing and commercializing two therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. Waqaas Al-Siddiq, ...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MYMD.
No results
No recent SID articles mention MYMD.
